|
시장보고서
상품코드
1587585
골형성 단백질 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 지역별, 부문별 예측(2025-2030년)Bone Morphogenetic Protein Market Size, Share & Trends Analysis Report By Type (rhBMP-2, rhBMP-7), By Application (Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial), By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
골형성 단백질 시장 성장과 동향:
Grand View Research, Inc.의 최신 보고서에 따르면 세계 골형성 단백질 시장 규모는 2025년부터 2030년까지 4.93%의 CAGR로 2030년까지 4억 5,990만 달러에 달할 것으로 예상됩니다.
척추 고정술, 외상, 소골 수술의 발생률 증가와 더 빠른 뼈 회복에 대한 수요는 BMP 시장의 성장을 보장하는 주요 요인입니다.
요통과 척추 추간판탈출증은 가장 흔한 직업병 중 하나입니다. 이러한 장애의 75% 이상은 비침습적 치료로 완화되지 않고 척추 수술이 필요합니다. 최소침습 수술, 짧은 입원 기간, 빠른 회복은 환자들 사이에서 흔히 볼 수 있는 요구 사항이며, BMP는 위와 같은 장점으로 인해 최근 몇 년 동안 정형외과 의사들 사이에서 높은 지지를 받고 있습니다.
스포츠 관련 부상, 고령 인구의 증가, 뼈 이식을 대체할 수 있는 뼈 유도 제품에 대한 인식이 높아진 것도 시장 성장을 촉진하는 요인이며, BMP는 기증자의 이환율 부족, 대규모 수술 절차, 높은 회복 시간, 통증과 마비, 높은 비용 등 뼈 이식보다 우수한 결과를 보고하고 있습니다.
골형성 단백질 시장 보고서 하이라이트:
- rhBMP-2와 rhBMP-7은 시판되는 재조합 BMP로, rhBMP-2는 골유합술에서 뼈와 연골의 형성을 촉진하는 높은 골유도성을 가지고 있는 것으로 널리 알려져 있습니다.
- rhBMP-2 부문은 2024년 73.9%의 가장 큰 시장 점유율을 차지했으며, 2025년부터 2030년까지 더 높은 CAGR로 성장할 것으로 예상됩니다.
- rhBMP-7 부문은 2025년부터 2030년까지 완만한 CAGR로 성장할 것으로 예상됩니다. 의료 전문가들이 뼈 복구를 위해 자가 이식에 대한 대안을 찾는 경향이 증가함에 따라 이식편 채취와 관련된 합병증 없이 치유를 촉진하는 rhBMP-7의 능력은 임상 현장에서의 채택을 촉진할 수 있습니다.
- 척추 고정술 분야는 2024년 50.3%의 가장 큰 시장 점유율을 차지했습니다. 이러한 성장의 배경에는 효과적이고 효율적인 솔루션의 개발, 기존 치료법보다 이러한 단백질이 더 많이 수용되고 있으며, 시장에서의 입지를 강화하기 위한 연구 이니셔티브가 진행 중이라는 점 등이 있습니다.
- 북미는 2024년 골형성 단백질 세계 시장에서 49.6%의 가장 큰 시장 점유율을 차지했습니다. 높은 정형외과 수술 건수와 유리한 상환 정책을 이용할 수 있다는 점이 최대 점유율의 요인으로 작용하고 있습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장 변수, 동향, 범위
- 시장 계통 전망
- 상부 시장 전망
- 관련/부수 시장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 업계 분석 툴
- Porter's Five Forces 분석
- PESTEL 분석
- COVID-19의 영향 분석
제4장 골형성 단백질 시장 : 유형별 비즈니스 분석
- 유형 부문 대시보드
- 세계의 골형성 단백질 시장 유형 변동 분석
- 세계의 골형성 단백질 시장 규모와 동향 분석, 유형별, 2018-2030년
- rHBMP-2 유전자
- rHBMP-7 유전자
제5장 골형성 단백질 시장 : 용도 비즈니스 분석
- 용도 부문 대시보드
- 세계의 골형성 단백질 시장 용도 변동 분석
- 세계의 골형성 단백질 시장 규모와 동향 분석, 용도별, 2018-2030년
- 척추 고정술
- 외상
- 재건
- 구강악안면
제6장 골형성 단백질 시장 : 유형과 용도별 지역 추정·동향 분석
- 지역 대시보드
- 시장 규모와 예측 및 동향 분석, 2018-2030년
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제7장 경쟁 상황
- 진출 기업
- 전략 매핑
- 기업 시장 상황 분석, 2024년
- 진출 기업 개요
- Medtronic plc
- Cellumed Co., Ltd.
- Cell Guidance Systems LLC
- Merck KGaA
- Prospec-Tany Technogene Ltd.
- Qkine Ltd.
- Bio-Techne.
- Thermo Fisher Scientific Inc.
- Proteintech Group, Inc.
- STEMCELL Technologies
- Sartorius Stedim Biotech
Bone Morphogenetic Protein Market Growth & Trends:
The global bone morphogenetic protein market size is expected to reach USD 459.9 million by 2030, registering a CAGR of 4.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of spinal fusion, trauma, and small bone surgeries coupled with demand for faster bone recovery are the key drivers affirming growth of BMP market.
Low back pain and spinal disc dislocation are some of the most common occupational hazards. Over 75% of such disorders require spinal surgery after noninvasive treatment options are unable to provide any relief. Minimally invasive surgery, shorter hospital stays, and fast recovery are common demands observed among patients. BMP has gained high acceptance among orthopedic surgeons in recent years owing to its ability to cater above mentioned benefits
Sport-related injuries, growing geriatric population, and increasing awareness about osteoinduction products as an alternative to bone grafting are other drivers accentuating market growth. BMP has reported outstanding results over bone graft, such as lack of donor morbidity, extensive surgical procedure, higher recovery time, pain & numbness, and high cost.
Bone Morphogenetic Protein Market Report Highlights:
- rhBMP-2 and rhBMP-7 are the commercially available recombinant BMPs. rhBMP-2 is widely known for its high osteoinductive property for faster formation of bone and cartilage in bone fusion procedures.
- The rhBMP-2 segment held the largest market share of 73.9% in 2024 and is anticipated to grow at the higher CAGR from 2025 to 2030.
- rhBMP-7 segment is expected to grow at a moderate CAGR from 2025 to 2030. As healthcare professionals increasingly look for alternatives to autografts for bone repair, rhBMP-7's ability to promote healing without the complications associated with harvesting grafts could drive its adoption in clinical practice.
- The spinal fusion segment held the largest market share of 50.3% in 2024. The growth is attributed to the development of effective and efficient solutions, the increasing acceptance of these proteins over conventional treatments, and the ongoing research initiatives that strengthen their position in the market.
- North America held the largest market share of 49.6% in the global bone morphogenetic protein market in 2024. High number of orthopedic surgical procedures, and availability of favorable reimbursement policies are drivers that can be attributed to for largest share.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Application Segment
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing demand for minimally invasive medical procedures
- 3.2.1.2. Increasing incidence of sports-related injuries
- 3.2.1.3. Increasing target population
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Complications associated with the use of Bone Morphogenic Proteins
- 3.2.2.2. Availability of alternative treatments
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Bone Morphogenetic Protein Market: Type Business Analysis
- 4.1. Type Segment Dashboard
- 4.2. Global Bone Morphogenetic Protein Market Type Movement Analysis
- 4.3. Global Bone Morphogenetic Protein Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. rhBMP-2
- 4.4.1. Global rhBMP-2 Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. rhBMP-7
- 4.5.1. Global rhBMP-7 Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Bone Morphogenetic Protein Market: Application Business Analysis
- 5.1. Application Segment Dashboard
- 5.2. Global Bone Morphogenetic Protein Market Application Movement Analysis
- 5.3. Global Bone Morphogenetic Protein Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Spinal Fusion
- 5.4.1. Global Spinal Fusion Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Trauma
- 5.5.1. Global TraumaMarket Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Reconstruction
- 5.6.1. Global Reconstruction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Oral Maxillofacial
- 5.7.1. Global Oral Maxillofacial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Bone Morphogenetic Protein Market: Regional Estimates & Trend Analysis by Type and Application
- 6.1. Regional Dashboard
- 6.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 6.3. North America
- 6.3.1. North America Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Key Country Dynamics
- 6.3.2.2. Market and Competitive Scenario
- 6.3.2.3. U.S. Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Canada
- 6.3.3.1. Key Country Dynamics
- 6.3.3.2. Market and Competitive Scenario
- 6.3.3.3. Canada Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. Mexico
- 6.3.4.1. Key Country Dynamics
- 6.3.4.2. Market and Competitive Scenario
- 6.3.4.3. Mexico Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Europe
- 6.4.1. Europe Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. UK
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Market and Competitive Scenario
- 6.4.2.3. UK Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Germany
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Market and Competitive Scenario
- 6.4.3.3. Germany Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. France
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Market and Competitive Scenario
- 6.4.4.3. France Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Italy
- 6.4.5.1. Key Country Dynamics
- 6.4.5.2. Market and Competitive Scenario
- 6.4.5.3. Italy Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Spain
- 6.4.6.1. Key Country Dynamics
- 6.4.6.2. Market and Competitive Scenario
- 6.4.6.3. Spain Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Denmark
- 6.4.7.1. Key Country Dynamics
- 6.4.7.2. Market and Competitive Scenario
- 6.4.7.3. Denmark Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.8. Sweden
- 6.4.8.1. Key Country Dynamics
- 6.4.8.2. Market and Competitive Scenario
- 6.4.8.3. Sweden Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.9. Norway
- 6.4.9.1. Key Country Dynamics
- 6.4.9.2. Market and Competitive Scenario
- 6.4.9.3. Norway Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Japan
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Market and Competitive Scenario
- 6.5.2.3. Japan Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. China
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Market and Competitive Scenario
- 6.5.3.3. China Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. India
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Market and Competitive Scenario
- 6.5.4.3. India Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.5. Australia
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Market and Competitive Scenario
- 6.5.5.3. Australia Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.6. Thailand
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Market and Competitive Scenario
- 6.5.6.3. Thailand Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.7. South Korea
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Market and Competitive Scenario
- 6.5.7.3. South Korea Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Brazil
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Market and Competitive Scenario
- 6.6.2.3. Brazil Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Market and Competitive Scenario
- 6.6.3.3. Argentina Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. MEA
- 6.7.1. MEA Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Market and Competitive Scenario
- 6.7.2.3. South Africa Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. Saudi Arabia
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Market and Competitive Scenario
- 6.7.3.3. Saudi Arabia Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.4. UAE
- 6.7.4.1. Key Country Dynamics
- 6.7.4.2. Market and Competitive Scenario
- 6.7.4.3. UAE Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.5. Kuwait
- 6.7.5.1. Key Country Dynamics
- 6.7.5.2. Market and Competitive Scenario
- 6.7.5.3. Kuwait Bone Morphogenetic Protein Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Participant Categorization
- 7.2. Strategy Mapping
- 7.3. Company Market Position Analysis, 2024
- 7.4. Participant's Overview
- 7.4.1. Medtronic plc
- 7.4.1.1. Overview
- 7.4.1.2. Financial Performance
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Strategic Initiatives
- 7.4.2. Cellumed Co., Ltd.
- 7.4.2.1. Overview
- 7.4.2.2. Financial Performance
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Strategic Initiatives
- 7.4.3. Cell Guidance Systems LLC
- 7.4.3.1. Overview
- 7.4.3.2. Financial Performance
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Strategic Initiatives
- 7.4.4. Merck KGaA
- 7.4.4.1. Overview
- 7.4.4.2. Financial Performance
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Strategic Initiatives
- 7.4.5. Prospec-Tany Technogene Ltd.
- 7.4.5.1. Overview
- 7.4.5.2. Financial Performance
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Strategic Initiatives
- 7.4.6. Qkine Ltd.
- 7.4.6.1. Overview
- 7.4.6.2. Financial Performance
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Strategic Initiatives
- 7.4.7. Bio-Techne.
- 7.4.7.1. Overview
- 7.4.7.2. Financial Performance
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Strategic Initiatives
- 7.4.8. Thermo Fisher Scientific Inc.
- 7.4.8.1. Overview
- 7.4.8.2. Financial Performance
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Strategic Initiatives
- 7.4.9. Proteintech Group, Inc.
- 7.4.9.1. Overview
- 7.4.9.2. Financial Performance
- 7.4.9.3. Product Benchmarking
- 7.4.9.4. Strategic Initiatives
- 7.4.10. STEMCELL Technologies
- 7.4.10.1. Overview
- 7.4.10.2. Financial Performance
- 7.4.10.3. Product Benchmarking
- 7.4.10.4. Strategic Initiatives
- 7.4.11. Sartorius Stedim Biotech
- 7.4.11.1. Overview
- 7.4.11.2. Financial Performance
- 7.4.11.3. Product Benchmarking
- 7.4.11.4. Strategic Initiatives
- 7.4.1. Medtronic plc
